ストックスクリーナーアプリを入手
5.46
1.44%
-0.08
アフターアワーズ：
5.54
0.08
+1.47%
Sagimet Biosciences Inc (SGMT) 最新ニュース
Falcon Technoprojects India Limited Chart Enters High Volatility ZoneTake Profit Strategies & Fast Growing Trading Ideas - earlytimes.in
Sagimet Biosciences Inc. (SGMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely - Yahoo Finance
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Disc Medicine (IRON) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $26 - 富途牛牛
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts - TipRanks
Why Sagimet Biosciences Inc. stock could rally in 2025Gap Up & Verified Entry Point Detection - Улправда
Why retail investors favor Sagimet Biosciences Inc. stockJuly 2025 Drop Watch & Low Risk Profit Maximizing Plans - bolumsonucanavari.com
Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 5.4%Still a Buy? - MarketBeat
Fundamentals Check: Why Sagimet Biosciences Inc. stock could be next big winner - Улправда
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT) - Seeking Alpha
Can Sagimet Biosciences Inc. stock maintain growth trajectoryJuly 2025 Levels & Daily Entry Point Trade Alerts - DonanımHaber
Can Sagimet Biosciences Inc. stock beat market expectations this quarterJuly 2025 Fed Impact & Stock Market Timing Techniques - DonanımHaber
Sagimet reports positive Phase 1 results for MASH combination therapy By Investing.com - Investing.com Australia
How Sagimet Biosciences Inc. stock performs in high volatility marketsPrice Action & Low Volatility Stock Suggestions - DonanımHaber
Guidance Update: Why Sagimet Biosciences Inc. stock could be next big winner - Улправда
How Sagimet Biosciences Inc. (0O2) stock compares with top peersWeekly Investment Summary & Daily Chart Pattern Signals - Улправда
Investment Review: Why Sagimet Biosciences Inc. stock could be next big winnerMarket Sentiment Review & Fast Exit and Entry Trade Guides - Улправда
Sagimet Highlights Positive MASH Combo Data and Pipeline Progress - TipRanks
Sagimet reports positive Phase 1 results for MASH combination therapy - Investing.com India
Sagimet Biosciences Announces Positive Phase 1 PK Trial Results - TradingView — Track All Markets
[8-K] Sagimet Biosciences Inc. Reports Material Event | SGMT SEC FilingForm 8-K - Stock Titan
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination - The Manila Times
Sagimet Biosciences Announces Positive Results from the - GlobeNewswire
Sagimet Biosciences (Nasdaq:SGMT) Secures Global License for Resmetirom API in Combination Program - Kalkine Media
Sagimet Biosciences enters global license agreement with TAPI - MSN
Strategic Licensing and Pipeline Advancements Drive Buy Rating for Sagimet Biosciences - TipRanks
Sagimet Biosciences Signs License Agreement With Teva Subsidiary for Resmetirom Development - marketscreener.com
TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development - GuruFocus
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program - The Manila Times
Sagimet Biosciences Inc Enters License Agreement with TAPI - TradingView — Track All Markets
Sagimet Biosciences (NASDAQ: SGMT) signs TAPI deal for resmetirom API combo - Stock Titan
Sagimet Biosciences and TAPI Announce Global License - GlobeNewswire
Sagimet Biosciences Earnings Notes - Trefis
What the Technical Setup Suggests for HCKK Ventures Limited in the Next 30 Days - earlytimes.in
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio - Barchart.com
Sagimet Biosciences announces China’s NMPA accepted NDA for denifanstat - MSN
Sagimet's license partner Ascletis announced acceptance of new drug application for Denifanstat - marketscreener.com
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration - The Manila Times
Sagimet Biosciences Licenses Denifanstat for Acne Treatment to Ascletis Pharma as NMPA Accepts NDA in China - Quiver Quantitative
Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA - Stock Titan
SGMTSagimet Biosciences Inc. Latest Stock News & Market Updates - Stock Titan
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
A significant driver of top-line growth: Sagimet Biosciences Inc (SGMT) - Setenews
Sagimet Biosciences Inc (SGMT) stock on the rise: An overview - uspostnews.com
Is Sagimet Biosciences Inc. (0O2) stock worth holding before Fed meetingQuarterly Risk Review & Daily Risk Controlled Trade Plans - Newser
Is Sagimet Biosciences Inc. (0O2) stock prepared for digital transitionWeekly Trade Analysis & Low Risk High Reward Trade Ideas - Newser
How Sagimet Biosciences Inc. (0O2) stock trades after earningsTrade Ideas & Verified Technical Trade Signals - Newser
How cyclical is Sagimet Biosciences Inc. (0O2) stock compared to rivalsJuly 2025 WrapUp & Accurate Trade Setup Notifications - Newser
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):